Add another name to the list: In mid-November the beleaguered biotech outfit ImClone Systems Inc. announced the resignation of John Landes, the company’s senior vice president for legal affairs.
Resignation marked the end of a long, difficult stretch for Landes. Early last year-months before the allegations of insider trading against the company became public–Landes was demoted from general counsel to senior vice president. Then, in July, congressional investigators added Landes’s name to the roster of insiders alleged to have sold ImClone stock days before the company announced the Food and Drug Administration’s rejection of its application to market a cancer drug. Finally, last October, the House Energy and Commerce Committee ridiculed Landes and other ImClone directors and officers for not sniffing out wrongdoing at ImClone earlier.
